LGALS3 and cancer: Patients with poorly differentiated G3 cancer had significantly higher median galectin-3 levels (IIIB, LVSI+, G2-G3, median 22.6 ng/mL) than patients with well-differentiated cancer (IA, LVSI-, G1, median 15.7 ng/mL).